Para-aminosalicylic acid (Rezipas)

Synonym(s): Paramycin

Class: Mycolic acid synthesis inhibitor

Details of activity:	Active against Mycobacterium tuberculosis; mycobacterial folic acid synthesis inhibitor
Combined with other compounds:	Yes
Description:	Synthetic compound; prodrug; shows toxic side-effects such as gastrointestinal issues and intolerance during human clinical trials; second-line anti-TB drug
Institute where first reported:	BRISTOL MYERS SQUIBB
Year first mentioned:	1946
Highest developmental phase:	Clinical Trial (1950; with streptomycin or isoniazid from 1950-1964)
Development status:	Discontinued

Chemical structure(s):
Canonical SMILES:	C1=C(C=C(C(=C1)C(=O)O)O)N
Isomeric SMILES:	C1=CC(=C(C=C1N)O)C(=O)O
InChI:	InChI=1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)
InChI Key:	WUBBRNOQWQTFEX-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/4649

External links:
Main Source:	https://www.sciencedirect.com/science/article/pii/S0140673646911853
Citations:	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(15)00263-7/fulltext https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395024/#B3